The use of agonistic anti-CD40 therapy in treatments for cancer.
about
Immunotherapy for lung cancermTOR kinase inhibitors as potential cancer therapeutic drugsSerial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomesAgonistic anti-CD40 induces thyrocyte proliferation and promotes thyroid autoimmunity by increasing CD40 expression on thyroid epithelial cells.Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies.CD40 therapy and surgery: a potential immunologic partnership.Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinomaDirect T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.The nature of activatory and tolerogenic dendritic cell-derived signal II.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study.Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.Considerations for successful cancer immunotherapy in aged hosts.Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.Effects of CD40 ligation combined with chemotherapy drugs on human breast cancer cell lines.Development of CAR T cells designed to improve antitumor efficacy and safety.Regulatory role of CD40 in obesity-induced insulin resistance.Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS.Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.Elderly dendritic cells respond to LPS/IFN-γ and CD40L stimulation despite incomplete maturation.Bispecific antibodies in cancer immunotherapyA tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
P2860
Q26751254-50BC0CED-D6B0-4D73-A5B6-90ED6ADCFE9FQ27027963-6DCF0A10-2751-4A33-81F6-C3E6DB6B7752Q33805073-94A6C6F7-013F-435B-80B4-ED72A904600AQ35060384-198F692B-A9AD-4229-9AF7-99F9234F1B5DQ35130794-F7C8F01C-9BE5-4BC0-A084-AEAE734D0E24Q35399334-0CA56934-60AF-4EEA-B01B-4B90E5FEF72BQ36711060-EDBB5D0E-8910-4971-BB3B-80D22294221DQ36754417-9AE1DBC3-1892-4F27-B113-32ABE206BE74Q36821113-923C5462-0890-4E1E-86DF-1819871651EAQ37226420-FDD98538-49F0-4717-B10E-1FAB118D1E24Q37416204-276B75DD-5C41-494D-A2C8-9756263930BBQ37617052-5BA3C593-153D-46FE-AC1C-1AABFFF16096Q37659577-10521CF8-7511-437B-BFB8-395C348F028DQ38085577-7088569D-E865-403F-8365-7F2072A42B35Q38120535-D10E74B6-FA8F-48CD-B65D-2F4BB8C14190Q38727923-65778558-986D-4425-8AE0-B7411F6D3FDDQ38779032-564D1202-DD51-488E-B00C-929CD4525D89Q38815953-EC8980FC-7301-4A71-91AF-523D8BA3708CQ39003293-3C6228DB-984E-4E1C-8A9C-B8803C8B077DQ39112311-E4F29B2A-F3B4-43FC-8FA2-2A8B3B7A511AQ39200527-5210DC7F-653B-44A5-AA65-8A7E4424B0CFQ41179559-293C9C03-2010-4C21-BEAD-E0F43EEE35F1Q47153937-FA2E9199-C921-4449-A1B2-C1F66DA7BD78Q48120429-CF6DA90A-62CA-4CB2-A082-022B029808B7Q55154202-F133EC10-C187-4CD8-9469-19DD9ABA84AFQ56893015-08A63BD2-DB0F-4EA2-9041-65D0391338B2Q59136671-85EE46E1-0AC8-4294-B8D4-6BCB7FCCF9A5
P2860
The use of agonistic anti-CD40 therapy in treatments for cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The use of agonistic anti-CD40 therapy in treatments for cancer.
@en
type
label
The use of agonistic anti-CD40 therapy in treatments for cancer.
@en
prefLabel
The use of agonistic anti-CD40 therapy in treatments for cancer.
@en
P2093
P2860
P1476
The use of agonistic anti-CD40 therapy in treatments for cancer.
@en
P2093
Andrea Khong
Anna K Nowak
Bruce W S Robinson
Delia J Nelson
Richard A Lake
P2860
P304
P356
10.3109/08830185.2012.698338
P577
2012-08-01T00:00:00Z